Over the next decade, CRISPR and other forms of gene editing could help people with rare disorders — and millions more with heart disease, diabetes, and chronic pain

Print Friendly, PDF & Email
Credit: Science Photo Library/Getty Images
Credit: Science Photo Library/Getty Images

In the next decade, Crispr-Cas9 and other new gene-editing techniques may protect the health [of] millions of people with a range of conditions, including chronic pain and diabetes. Rather than take drugs for years or even decades, for example, at-risk people might be able to protect themselves with a one-and-done Crispr therapy.

Scientists reported last December that gene-edited cells curbed severe pain and other symptoms in a small number of patients with sickle cell disease and beta-thalassemia, two rare, inherited blood disorders.

Verve Therapeutics, a Cambridge, Mass.-based startup, presented animal research in 2020 showing that a Crispr-based therapy for cardiovascular disease reduced levels of LDL, or “bad” cholesterol, by an average of 61%. Crispr Therapeutics, a Swiss company, and a partner plan to test a Crispr therapy for diabetes: An under-the-skin implant containing Crispr-edited cells that will deliver insulin, with the goal of eliminating injections and regular testing of glucose levels.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

“We showed Crispr gene editing works in humans,” [physician Dr. Haydar] Frangoul says. “We made a crack in the door. The crack is getting wider.”

Read the original post

Related article:  Viewpoint: ‘It’s not a political statement’ – Former FDA chief Scott Gottlieb calls for nationwide mask mandate
Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

The U.S. averaged fewer than 40,000 new cases per day over the past week. That’s a 21% improvement over the ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists